Skip to main content
. 2019 Dec 2;16(1):186–197. doi: 10.1007/s12015-019-09925-z

Table 2.

Basal evaluations (V0) and acute safety outcomes (V1-V3) in one patient affected by argininosuccinate lyase (ASL) deficiency and two patients with methylmalonic acidemia treated by intrahepatic injections of human liver stem cells (HLSCs)

Patient 1 (ASL deficiency) Patient 2 and 3 (Methylmalonic acidemia) All patients
HLSCs dose 125,000 cells/g of liver 250,000 cells/g of liver
Visit V0 V1 V2 V3 V0 V1 V2 V3 V0 V1 V2 V3
Clinical parameters
Blood pressure (mmHg) 91/52 90/52 75/48 72/40 73 ± 23/43 ± 23 90 ± 0/48 ± 4 80 ± 7/52 ± 10 85 ± 7/50 ± 0 79 ± 19/46 ± 17 90 ± 0/49 ± 3 75 ± 9/48 ± 10 80 ± 9/46 ± 5
Temperature (°C) 36.1 36.3 36.7 36.0 36.3 ± 0.1 36.3 ± 0.1 36.7 ± 0.7 36.2 ± 0.2 36.1 ± 0.1 36.1 ± 0.6 36.7 ± 0.2 36.1 ± 0.2
Heart rate 131 135 116 140 98 ± 2 100 ± 0 97 ± 1 99 ± 0 121 ± 9 137 ± 28 116 ± 24 139 ± 7
Respiratory rate 45 55 47 40 55 ± 7 47 ± 18 50 ± 14 54 ± 8 51 ± 7 49 ± 13 47 ± 10 49 ± 10
Saturation O2(%) 99 100 98 98 98 ± 2 100 ± 0 97 ± 1 99 ± 0 98 ± 2 100 ± 0 98 ± 2 99 ± 1
Laboratory tests
Red blood cells (1012/l) 4.0 3.9 3.8 4.0 3.6 ± 0.0 4.4 ± 0.4 4.4 ± 0.1 4.4 ± 0.4 3.7 ± 0.2 4.3 ± 0.4 4.2 ± 0.3 4.3 ± 0.3
Hemoglobin (g/dl) 10.9 10.0 10.1 10.1 7.9 ± 0.3 10.6 ± 2.4 9.9 ± 0.7 9.5 ± 0.0 8.9 ± 1.7 10.4 ± 1.7 9.9 ± 0.5 9.7 ± 0.3
Platelets (109/l) 720 574 761 458 763 ± 30 484 ± 48 588 ± 186 502 ± 38 749 ± 33 514 ± 62 645 ± 165 487 ± 37
White blood cells (109/l) 12.4 19.8 12.4 11.8 8.8 ± 1.6 7.1 ± 0.3 10.0 ± 3.4 9.1 ± 4.6 10.0 ± 2.2 11.3 ± 7.3 10.8 ± 2.7 10.0 ± 3.6
INR 1.1 1.0 1.0 0.9 1.0 ± 0.2 1.0 ± 0.2 1.0 ± 0.2 1.0 ± 0.1 1.1 ± 0.2 1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.0
AST (U/l) 32 37 65 43 41 ± 22 32 ± 4 33 ± 9 37 ± 14 38 ± 16 33 ± 4 43 ± 20 39 ± 10
ALT (U/l) 34 33 39 25 39 ± 18 32 ± 4 34 ± 16 37 ± 23 37 ± 13 32 ± 3 36 ± 11 33 ± 18

International normalized ratio (INR, normal range 0.8–1.2); Aspartate aminotransferase (AST, normal range: 20–50 U/l); Alanine aminotransferase (ALT, normal range: 20–50 U/l)